-
Callen J, Paes BA, 2007: A case report of a premature infant with coxsackie b1 meningitis[J]. Adv Neonatal Care, 7, 238-247. doi: 10.1097/01.ANC.0000296631.80926.8d
-
Cao L, Mao F, Pang Z, Yi Y, Qiu F, Tian R, Meng Q, Jia Z, Bi S, 2015: Protective effect of enterovirus-71 (ev71) virus-like particle vaccine against lethal ev71 infection in a neonatal mouse model[J]. Mol Med Rep, 12, 2473-2480. doi: 10.3892/mmr.2015.3680
-
C DC, 2008: Increased detections and severe neonatal disease associated with coxsackievirus b1 infection-united states, 2007[J]. MMWR, 57, 553-556.
-
C DC, 2010: Nonpolio enterovirus and human parechovirus surveillancejunited states, 2006-2008[J]. MMWR, 59, 1577-1580.
-
Chen W, Weng YW, Zhang YJ, He WX, Zhu Y, Yu TT, Xie JF, Zheng KC, Yan YS, Zhang WC, 2019: Molecular epidemiology of coxsackievirus b1-5 associated with hfmd in fujian province, china, 2011-2016[J]. Biomed Environ Sci, 32, 633-638.
-
Goren A, Kaplan M, Glaser J, Isacsohn M, 1989: Chronic neonatal coxsackie myocarditis[J]. Arch Dis Child, 64, 404-406. doi: 10.1136/adc.64.3.404
-
Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Määttä JAE, Larsson PG, Marjomäki V, Hyöty H, Flodström-Tullberg M, Hytönen VP, 2017: Optimized production and purification of coxsackievirus b1 vaccine and its preclinical evaluation in a mouse model[J]. Vaccine, 35, 3718-3725. doi: 10.1016/j.vaccine.2017.05.057
-
Hankaniemi MM, Stone VM, Sioofy-Khojine AB, Heinimäki S, Marjomäki V, Hyöty H, Blazevic V, Laitinen OH, Flodström-Tullberg M, Hytönen VP, 2019b: A comparative study of the effect of uv and formalin inactivation on the stability and immunogenicity of a coxsackievirus b1 vaccine[J]. Vaccine, 37, 5962-5971. doi: 10.1016/j.vaccine.2019.08.037
-
Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine AB, Marjomäki V, Hyöty H, Blazevic V, Flodström-Tullberg M, Hytönen VP, Laitinen OH, 2019: Formalin treatment increases the stability and immunogenicity of coxsackievirus b1 vlp vaccine[J]. Antivir Res, 171, 104595-. doi: 10.1016/j.antiviral.2019.104595
-
Heinimäki S, Hankaniemi MM, Sioofy-Khojine AB, Laitinen OH, Hyöty H, Hytönen VP, Vesikari T, Blazevic V, 2019: Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus[J]. Vaccine, 37, 7509-7518. doi: 10.1016/j.vaccine.2019.09.072
-
Hindersson M, Orn A, Harris RA, Frisk G, 2004: Strains of coxsackie virus b4 differed in their ability to induce acute pancreatitis and the responses were negatively correlated to glucose tolerance[J]. Arch Virol, 149, 1985-2000.
-
Hober D, Alidjinou EK, 2018: Diabetes: towards a coxsackievirus b-based vaccine to combat t1dm[J]. Nat Rev Endocrinol, 14, 131-132. doi: 10.1038/nrendo.2017.184
-
Ji H, Fan H, Lu PX, Zhang XF, Ai J, Shi C, Huo X, Bao CJ, Shan J, Jin Y, 2019: Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in jiangsu province: Epidemiology, etiology, and disease burden[J]. BMC Infect Dis, 19, 79-. doi: 10.1186/s12879-018-3659-7
-
Jin Y, Zhang C, Zhang R, Ren J, Chen S, Sui M, Zhou G, Dang D, Zhu J, Feng H, Xi Y, Yang H, Duan G, 2017: Pulmonary edema following central nervous system lesions induced by a non- mouse-adapted ev71 strain in neonatal balb/c mice[J]. Virol J, 14, 243-. doi: 10.1186/s12985-017-0911-5
-
Kim H, Kang B, Hwang S, Hong J, Chung J, Kim S, Jeong YS, Kim K, Cheon DS, 2013: Molecular characteristics of human coxsackievirus b1 infection in korea, 2008-2009[J]. J Med Virol, 85, 110-115. doi: 10.1002/jmv.23359
-
Larsson PG, Lakshmikanth T, Laitinen OH, Utorova R, Jacobson S, Oikarinen M, Domsgen E, Koivunen MRL, Chaux P, Devard N, Lecouturier V, Almond J, Knip M, Hyöty H, Flodström-Tullberg M, 2015: A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus b1 reveals no risk for accelerated diabetes development in mouse models[J]. Diabetologia, 58, 346-354. doi: 10.1007/s00125-014-3436-0
-
Li S, Zhao H, Yang L, Hou W, Xu L, Wu Y, Wang W, Chen C, Wan J, Ye X, Liang Z, Mao Q, Cheng T, Xia N, 2017: A neonatal mouse model of coxsackievirus a10 infection for anti-viral evaluation[J]. Antivir Res, 144, 247-255. doi: 10.1016/j.antiviral.2017.06.008
-
Lu JC, Koay KW, Ramers CB, Milazzo AS, 2005: Neonate with coxsackie b1 infection, cardiomyopathy and arrhythmias[J]. J Natl Med Assoc, 97, 1028-1030.
-
Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J, 2012: A neonatal mouse model of coxsackievirus a16 for vaccine evaluation[J]. J Virol, 86, 11967-11976. doi: 10.1128/JVI.00902-12
-
Oikarinen S, Tauriainen S, Hober D, Lucas B, Vazeou A, Sioofy-Khojine A, Bozas E, Muir P, Honkanen H, Ilonen J, Knip M, Keskinen P, Saha M-T, Huhtala H, Stanway G, Bartsocas C, Ludvigsson J, Taylor K, Hyöty H, 2014: Virus antibody survey in different european populations indicates risk association between coxsackievirus b1 and type 1 diabetes[J]. Diabetes, 63, 655-662. doi: 10.2337/db13-0620
-
Op de Beeck A, Eizirik DL, 2016: Viral infections in type 1 diabetes mellitus-why the β cells?[J]. Nat Rev Endocrinol, 12, 263-273. doi: 10.1038/nrendo.2016.30
-
Reed LJ, Hugo M, 1938: A simple method of estimating fifty per cent endpoints[J]. Am J Hyg, 27, 493-497.
-
Sioofy-Khojine AB, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala H, Pakkanen O, Ruokoranta T, Hankaniemi MM, Toppari J, Vähä-Mäkilä M, Ilonen J, Veijola R, Knip M, Hyöty H, 2018: Coxsackievirus b1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes[J]. Diabetologia, 61, 1193-1202. doi: 10.1007/s00125-018-4561-y
-
Stene LC, Oikarinen S, Hyöty H, Barriga KJ, Norris JM, Klingensmith G, Hutton JC, Erlich HA, Eisenbarth GS, Rewers M, 2010: Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the diabetes and autoimmunity study in the young (daisy)[J]. Diabetes, 59, 3174-3180. doi: 10.2337/db10-0866
-
Stone VM, Hankaniemi MM, Svedin E, Sioofy-Khojine A, Oikarinen S, Hyöty H, Laitinen OH, Hytönen VP, Flodström-Tullberg M, 2018: A coxsackievirus b vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes[J]. Diabetologia, 61, 476-481. doi: 10.1007/s00125-017-4492-z
-
Stone VM, Hankaniemi MM, Laitinen OH, Sioofy-Khojine AB, Lin A, Diaz Lozano IM, Mazur MA, Marjomäki V, LorȦ K, Hyöty H, Hytönen VP, Flodström-Tullberg M, 2020: A hexavalent coxsackievirus b vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates[J]. Sci Adv, 6, eaaz2433-. doi: 10.1126/sciadv.aaz2433
-
Tracy S, Höfling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ, 2000: Group b coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice[J]. J Med Virol, 62, 70-81. doi: 10.1002/1096-9071(200009)62:1<70::AID-JMV11>3.0.CO;2-R
-
Wikswo ME, Khetsuriani N, Fowlkes AL, Zheng X, Peñaranda S, Verma N, Shulman ST, Sircar K, Robinson CC, Schmidt T, Schnurr D, Oberste MS, 2009: Increased activity of coxsackievirus b1 strains associated with severe disease among young infants in the united states, 2007-2008[J]. Clin Infect Dis, 49, e44-e51. doi: 10.1086/605090
-
Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, Zhang HM, Suarez A, Yang D, McManus BM, 2004: Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice[J]. J Infect Dis, 189, 1431-1439. doi: 10.1086/382598
-
Zeng QX, Wang HQ, Wei W, Guo TT, Yu L, Wang YX, Li YH, Song DQ, 2020: Synthesis and biological evaluation of berberine derivatives as a new class of broad-spectrum antiviral agents against coxsackievirus b[J]. Bioorg Chem, 95, 103490-. doi: 10.1016/j.bioorg.2019.103490
-
Zhang Z, Dong Z, Wei Q, Carr MJ, Li J, Ding S, Tong Y, Li D, Shi W, 2017: A neonatal murine model of coxsackievirus a6 infection for evaluation of antiviral and vaccine efficacy[J]. J Virol, 91, e02450-e02416.
-
Zhang C, Zhang X, Dai W, Liu Q, Xiong P, Wang S, Geng L, Gong S, Huang Z, 2018: A mouse model of enterovirus d68 infection for assessment of the efficacy of inactivated vaccine[J]. Viruses, 10, 58-. doi: 10.3390/v10020058
-
Zhang L, Yan J, Ojcius DM, Lv H, Miao Z, Chen Y, Zhang Y, Yan J, 2013: Novel and predominant pathogen responsible for the enterovirus-associated encephalitis in eastern china[J]. PloS One, 8, e85023-. doi: 10.1371/journal.pone.0085023
-
Zhong Z, Li X, Zhao W, Tong L, Liu J, Wu S, Lin L, Zhang Z, Tian Y, Zhang F, 2008: Mutations at nucleotides 573 and 579 within 5'-untranslated region augment the virulence of coxsackievirus b1[J]. Virus Res, 135, 255-259. doi: 10.1016/j.virusres.2008.04.012